Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Carolien M. Beukhof1*, Tessa Brabander2, Francien H. van Nederveen3, Marie-Louise F. van Velthuysen3, Yolanda B. de Rijke1, Leo J. Hofland1, Gaston J. H. Franssen1, Lideke A. C. Fröberg2, Boen L. R. Kam1, W. Edward Visser1, Wouter W. de Herder1 and Robin P. Peeters1

Abstract

Background: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treatment for MTC, is usually well tolerated, but evidence on its effectiveness is very limited.

Methods: Retrospective evaluation of treatment effects of PRRT in a highly selected group of MTC patients, with progressive disease or refractory symptoms. In addition, a retrospective evaluation of uptake on historical 111In-DTPA-octreotide scans was performed in patients with detectable tumor size > 1 cm.

Results: Over the last 17 years, 10 MTC patients were treated with PRRT. Four out of 10 patients showed stable disease at first follow-up (8 months after start of therapy) whereas the other 6 were progressive. Patients with stable disease were characterized by a combination of both a high uptake on 111In-DTPA-octreotide scan (uptake grade ≥ 3) and a positive somatostatin receptor type 2a (SSTR2a) expression of the tumor by immunohistochemistry. Retrospective evaluation of historical 111In-DTPA-octreotide scans of 35 non-treated MTC patients revealed low uptake (uptake grade 1) in the vast majority of patients 31/35 (89%) with intermediate uptake (uptake grade 2) in the remaining 4/35 (11%).

Conclusions: PRRT using 177Lu-octreotate could be considered as a treatment in those patients with high uptake on 111In-DTPA-octreotide scan (uptake grade 3) and positive SSTR2a expression in tumor histology. Since this high uptake was present in a very limited number of patients, this treatment is only suitable in a selected group of MTC patients.

Keywords: Thyroid cancer, medullary, Peptide receptor radionuclide therapy, Lutetium, Receptors, somatostatin

Background

Patients and treatment

Medullary thyroid carcinoma (MTC), originating from calcitonin (CT)-producing parafollicular C cells, is a rare form of thyroid cancer that accounts for less than 5% of thyroid carcinomas [1]. In 25% of the cases, MTC is part of inherited disorders, such as multiple endocrine neoplasia 2a, 2b or familial MTC involving RET germline mutations. Locally unresectable tumor or distant metastases have limited systemic treatment options [2, 3]. Although the tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib have been shown to improve progression-free survival (PFS) [hazard ratio (HR), 0.46 and HR 0.28 respectively], grade 3 or 4 adverse events occur in a large number of patients (44% in vandetanib, 69% in cabozantinib) [3, 4]. Therefore, alternative systemic treatment options with less side effects are needed.

Somatostatin receptor (SSTR) expression has been reported in up to 85% of MTCs, particularly SSTR
subtypes 2, 3 and 5 [5–8], with 49% of MTCs showing expression of the SSTR2a subtype [5]. Somatostatin receptor scintigraphy with 111In-DTPA-octreotide (Octreoscan”), which has high affinity for SSTR2a, has been reported to show lesional uptake in 57–65% of MTC patients [9–11]. Therefore, targeting the tumor with a radionuclide using somatostatin analogs as a ligand seems to be an attractive option.

In midgut neuroendocrine tumors, peptide receptor radionuclide therapy (PRRT) resulted in a PFS rate at 20 months of 65% vs. 11% in the control group [12].

In MTC there is limited experience with PRRT treatment. A phase II trial in 31 patients with 90Y-DOTA-TOC, which also targets SSTR2a, reported a partial response (PR) in 29% of the patients [13]. In a second trial treating 7 MTC patients with 177Lu-octreotate, 3 patients had PR, 3 patients had stable disease (SD) and 1 patient progressive disease (PD) [14]. These results suggest that PRRT might be a useful treatment in patients with MTC, although the total number of treated patients is very limited so far. For that reason, we performed a retrospective evaluation of treatment with 177Lu-octreotate in our center, where it was used in a highly selected group of 10 MTC patients with progressive disease or high risk tumor localization. In addition, we evaluated possible predictors and pitfalls of 177Lu-octreotate treatment in MTC.

Methods
We retrospectively studied 10 consecutive patients with histologically proven MTC. Patients treated with 177Lu-octreotate between 2000 and 2017 had progressive metastatic MTC according to Response Evaluation Criteria In Solid Tumors 1.1 [15] (RECIST) or had high risk tumor localization (intracardial and compressive cervical tumor). The study was approved by the Institutional Review Board of the Erasmus Medical Center (127.545/ 1993/84) and written informed consent was obtained from participants.

We used the methods for 177Lu-octreotate therapy as described in detail previously [16]. Patients received an average of 4 cycles of 177Lu-octreotate, up to a cumulative dose of 27.8 to 29.6 GBq, with an interval of 6 to 10 weeks [17, 18]. Response to treatment was evaluated at a median of 8 months (3 months after the last cycle with 177Lu-octreotate) and subsequently at 3 monthly follow-up visits, assessing clinical, biochemical and imaging parameters. The world health organization (WHO) performance status was scored at baseline and during follow-up by the treating physician.

End points
PFS was computed as the time from treatment initiation to progression, assessed by objective tumor response RECIST 1.1 criteria, clinical disease progression according to the treating physician, death or last documented patient visit [15]. Overall survival (OS) was computed as the time from treatment initiation to death, or until the last documented patient visit. Adverse events were scored according to Common Terminology Criteria for Adverse Events [19].

111In-DTPA-octreotide scans
We retrospectively reviewed 111In-DTPA-octreotide scans between 1999 and 2011 of non-treated MTC patients that were performed in metastatic MTC. Although not part of the regular follow-up of MTC [2], 111In-DTPA-octreotide scans were performed for tumor staging in most of these patients. Uptake was scored according to the Krenning score [18, 20]: uptake grade 1 = uptake < normal liver uptake; uptake grade 2 = uptake equal to normal liver uptake; uptake grade 3 = uptake > normal liver uptake; uptake grade 4 = uptake > normal spleen or kidneys uptake (Fig. 1).

Immunohistochemistry SSTR2a
SSTR2a immunohistochemistry was retrospectively performed in the patients treated with 177Lu-octreotate. Formalin fixed paraffin embedded (FFPE) tissue slices of one or two tissue biopsies per patient were immunostained for SSTR2a using the Ventana BenchMark ULTRA stainer (Ventana, Tucson, Arizona, USA), according to the protocol provided by the manufacturer. The rabbit monoclonal anti-sst2 antibody (BioTrend, Köln, Germany) was used at a dilution of 1:25. Normal pancreatic tissue served as a positive control. SSTR2a expression was scored according to the percentage of cells with positive immunohistochemistry (0: absent staining; 1: weak staining < 30% of cells; 2: moderate staining 30–60% cells; 3: strong staining> 60% of cells) and localization cytoplasm or cell membrane [21]. Scoring was done by two independent pathologists (F.H. N and M.F.V), who were blinded to each other’s findings and patient data.

Laboratory measurements
RET gene analysis to exclude multiple endocrine neoplasia 2a, was performed in DNA of 6/10 patients. RET analysis on the tumor tissue was not performed in this retrospective study. Calcitonin (CT) and carcinoembryonic antigen (CEA) are useful tumor markers of residual disease and their doubling time is an indicator for prognosis [22]. CT was measured on an Immulite 2000XPi immunoassay system (Siemens Healthcare Diagnostics, Los Angeles, USA) by chemoluminescence method. CEA was measured by an electrochemiluminescence immunoassay on a Cobas e601 immunoassay analyzer (Roche Diagnostics GmbH, Penzberg, Germany). The
inter-day coefficient of variation of CT and CEA were 7.8 and 5%, respectively.

Statistics
We refrained from statistics due to limited patient number. PFS and OS was determined with Kaplan-Meier BM SPSS Statistics for Windows v23 (IBM Corp., Armonk, NY).

Results
Baseline
Ten patients were treated with $^{177}$Lu-octreotate. They had a median age 62 [range 19–75] years and 4/10 (40%) were male (Table 1). The indication for $^{177}$Lu-octreotate was progressive MTC according to RECIST-criteria in 8/10 (80%) of patients. One patient was treated for intracardial metastasis with biochemical progression and one patient for large cervical inoperable tumor load. None of the tested patients showed germline mutations in the RET proto-oncogene (Table 1). Eight out of 10 (80%) patients had a baseline WHO performance status of 1, whereas the other 2 treated patients had a WHO status of 3 (Table 1). Three out of 10 (30%) patients had an endocrine paraneoplastic syndrome due to tumor-produced adrenocorticotropic hormone (ACTH), resulting in ectopic Cushing’s disease, parathyroid hormone-related protein (PTH-rp) resulting in severe hypercalcemia and dopamine without clinical sequelae.

End points
Two patients showed PD during the third treatment cycle and were withheld from further treatment. In total, median PFS was 0.70 years [range 0.3–12.0], 1 patient is still in follow-up with stable disease 1.6 years after start of treatment. In total, 6 out of 10 (60%) patients had tumor progression at first follow-up (8 months) after start of treatment. The patient with large cervical inoperable tumor showed PD of distant metastasis, however the thyroid tumor mass with focal grade 3 expression on $^{111}$In-DTPA-octreotide scan remained stable.

Four out of 10 (40%) patients had SD at first follow-up. This includes, the patient with intracardial tumor mass with SD at start of therapy. Overall, SD was maintained for a median of 1.4 years [range 0.7–12.0] (Fig. 2). One patient with RECIST progressive disease before start of PRRT had enduring sustained SD for 12 years and died from an unrelated disease (fibrosarcoma). Overall median OS was 1.14 years [range 0.4–12.0]. Two patients are still alive at 1.4 and 1.6 years since start of PRRT. The median OS in SD patients was 1.8 years [0.8–12.0].

Baseline median CT doubling time and CEA doubling time showed a wide range making it difficult to interpret due to small patient number. Patients with SD seemed to have a trend to shorter CT and CEA doubling time than patients with PD (Table 1). None of the patients showed a decrease in CT or CEA levels of ≥50% after treatment with $^{177}$Lu-octreotate. Three of the four patients with SD showed a 20–40% decrease of CT and/or CEA levels with sustained response. One out of these four patients showed an initial rise of tumor markers in the first 5 months, which was followed by a sustained decrease in both tumor markers. Three out of the 6 patients with PD showed loss of correlation with CT (no increase in tumor marker, despite progressive disease) (Table 2). In one out of 6 patients there was loss of CEA tumor marker, but sustained CT response.

Predictors of response
All 4 patients with SD showed high uptake on the $^{111}$In-DTPA-octreotide scans (uptake grade ≥3) and showed moderate to positive SSTR2a receptor expression on histological examination (Table 2).

All patients with PD had negative tumor STTR2 expression in the tissue biopsy. Patients with PD had
variable uptake on $^{111}$In-DTPA-octreotide scans, as well as on post therapy scans (Table 2). Two out of 6 patients (33%) showed uptake grade 3 on $^{111}$In-DTPA-octreotide scan. In one of these patients we identified a remarkable SSTR2a positive staining of tumor endothelium. In 1 out of the 6 patients (17%) non-homogenous uptake of $^{111}$In-DTPA-octreotide scan, with loss of uptake in some metastasis was observed. In the other patients, 1/6 (17%) showed uptake grade 2 and 2/6 (33%) showed uptake grade 1 (Fig. 3).

$^{111}$In-DTPA-octreotide scans
None of the 35 retrospectively evaluated non-treated MTC patients had an $^{111}$In-DTPA-octreotide scan with higher uptake in the metastases than in the liver (grade ≥ 3). Only 4/35 (11%) patients showed moderate uptake (grade 2). In the majority of patients 31/35 (89%), the tumor was detectable. (Fig. 3).

Symptoms and adverse events
There was no improvement of symptoms or paraneoplastic syndrome, neither in the stable disease patients nor in the progressive patients. Common grade 1 side effects included diarrhea, fatigue, mild anorexia and mild hair loss, occurring in the majority of patients. Grade 2 diarrhea occurred in 1 out of 10 patients. One patient developed grade 3 adverse event: hemoptysis, presumably due to progression of pulmonary metastasis.

Discussion
This study reports the results of 10 patients with metastasized MTC that were treated with PRRT using $^{177}$Lu-octreotate. Only 4 patients showed SD at first follow-up at 8 months after start of therapy. All of these 4 patients with SD showed high uptake (Krenning uptake grade ≥ 3) on the $^{111}$In-DTPA-octreotide scan as well as SSTR2a receptor expression in the tumor upon immunohistochemistry staining, whereas none of the

### Table 1 Patient characteristics

|                        | Overall (N=10) | Stable disease (N=4) | Progressive disease (N=6) |
|------------------------|---------------|---------------------|--------------------------|
| Age years median [range]| 63 [19–75]   | 69 [19–75]          | 60 [42–73]               |
| Male N (%)             | 4/10 (40%)    | 1/4 (25%)           | 3/6 (50%)                |
| RET                    |               |                     |                          |
| Wild-type N (%)        | 6/10 (60%)    | 3/4 (75%)           | 3/6 (50%)                |
| Unknown N (%)          | 4/10 (40%)    | 1/4 (25%)           | 3/6 (50%)                |
| Disease extent         |               |                     |                          |
| Moderate               | 8/10 (80%)    | 2/4 (50%)           | 6/6 (100%)               |
| Extensive              | 2/10 (20%)    | 2/4 (50%)           | 0/6 (0%)                 |
| Tumormarkers           |               |                     |                          |
| Calcitonin DT years, [range] | 2.4 [0.6–4.1] | 0.8 [0.6–4.1] | 2.6 [2.4–2.9]            |
| CEA DT years, [range]  | 1.9 [0.6–7.4] | 1.9 [1.2–2.1]       | 4.0 [0.6–7.4]            |
| PRRT indication        |               |                     |                          |
| PD                     | 8/10 (70%)    | 3/4 (75%)           | 5/6 (83%)                |
| Tumor localization     | 2/10 (30%)    | 1/4 (25%)           | 1/6 (17%)                |
| WHO                    |               |                     |                          |
| 1                      | 8/10 (80%)    | 3/4 (75%)           | 5/6 (83%)                |
| 3                      | 2/10 (20%)    | 1/4 (25%)           | 1/6 (17%)                |
| Hormonal functioning   |               |                     |                          |
| 3/10 (30%)             | 1/4 (25%)     | 2/6 (33%)           |                          |
| Endpoints              |               |                     |                          |
| Death from MTC         | 7/10          | 2/4 (50%)           | 5/6 (83%)                |
| Death other cause      | 1/10          | 1/4 (25%)           | 0/4 (0%)                 |
| Alive                  | 2/10          | 1/4 (25%)           | 1/4 (25%)                |

Abbreviations: CEA, carcinoembryonic antigen; DT, doubling time; MTC, medullary thyroid carcinoma; N, number; PRRT, peptide receptor radionuclide therapy; RET, rearranged during transfection; WHO, world health organization performance status

Footnote:
● Intracardial metastasis and biochemical progression; inoperable cervical tumour load
● Ectopic ACTH; PTH-rp; dopamine
● Fibrosarcoma
remaining 6 patients that had PD at first follow-up had such a combination of high uptake plus SSTR2a receptor expression in the tumor. $^{177}$Lu-octreotate was well tolerated, in accordance to previous publications [12].

Our results are similar to the results reported with $^{90}$Yttrium-labelled octreotide treatment [13], where partial response (PR) was defined as any decrease in tumor marker. In the present study this was identified in 3 out of 10 (30%) patients. Moreover, median OS was in a similar range, i.e. 1.3 years in patients treated with $^{90}$Yttrium-labelled octreotide vs. 1.14 years in our study population. However, $^{90}$Yttrium-labelled octreotide is known to cause more severe hematological and renal side effects [13].

Although patient numbers are small, the study by Vaisman [14], suggests a better treatment response compared to the present study, where 6/10 (60%) patients had PD. PFS was 6.38 years in the study by Vaisman et al. versus 0.70 years in our patient population. This suggests that our study population included patients with more aggressive MTC. Several other study characteristics support this hypothesis. Firstly, the present study included 3/10 (30%) patients with paraneoplastic endocrine syndrome, which is a well-known poor prognostic factor [23]. Secondly 4/10 (40%) patients showed loss of tumor marker expression, which is also associated with worse prognosis [24]. And finally, our patients were much older (median age of 62 years [range 19–75] in the current study versus 35 years [range 20–78] in the study by Vaisman et al.), which is relevant, as age is an important determinant of prognosis in MTC [25].

The hypothesis that our study population had an aggressive form of MTC is also supported by the very low PFS in the present study, 0.7 years compared to 1.6 years in the placebo group of the phase III trial of the ZETA study (vandetanib) [4].

**Predictors of response**
All 4 patients with SD were characterized by high uptake on $^{111}$In-DTPA-octreotide scan (grade ≥ 3) and SSTR2a tumor expression.

**Table 2 Clinical characteristics and outcome**

|                     | Overall (N = 10) | Stable disease (N = 4) | Progressive disease (N = 6) |
|---------------------|-----------------|-----------------------|-----------------------------|
| Uptake Grade ≥ 3    | 7/10 (70%)      | 4/4 (100%)            | 3/6 (50%)                   |
| Uptake Grade < 3    | 3/10 (30%)      | 0/0 (0%)              | 3/6 (50%)                   |
| SSTR2a tumour expression | 4/10 (40%)     | 4/4 (100%)            | 0/6 (0%)                    |
| Loss of correlation CT | 3/6 (50%)      | 0/4 (0%)              | 3/6 (50%)                   |

**Abbreviations:** Calcitonin, CT; Grade 3: uptake > normal liver uptake; N, number; SSTR, somatostatin receptor
In the previously mentioned trial with $^{90}$Yttrium-labeled octreotide [14], tumor response did not correlate with $^{111}$In-DTPA-octreotide uptake. In that study only 2 out of 9 (22%) of the responders had a high uptake (grade $\geq 3$) vs. 6 out of 22 (27%) of the non-responders. However, response was based on tumor marker decrease and not scored according to RECIST criteria. SSTR2a staining on the tumor specimen was not performed.

Retrospective evaluation of historical $^{111}$In-DTPA-octreotide scans shows that only very few MTC patients have $^{111}$In-DTPA-octreotide scans with uptake grade $\geq 3$. Other papers have reported uptake in up to 65% of MTC patients, but none of these studies reported a formal uptake grade with comparison to hepatic uptake [9, 10].

Despite uptake grade $\geq 3$ on $^{111}$In-DTPA-octreotide scan, we identified 3/6 (50%) patients in the PD group who had negative SSTR2a tumor staining upon immunohistochemistry. This might be explained by non-homogenous tumor expression of the SSTR2a receptor. Moreover, in one of these patients with PD, we identified SSTR2a immunohistochemistry uptake in the vascular endothelium instead of in the tumor itself, which may have resulted in uptake on $^{111}$In-DTPA-octreotide scan. This phenomenon is described in a variety of other human tumors [26, 27].

In the present study SSTR2a expression was absent in all 6 patients with PD, which suggests that lack of SSTR2a expression in the tissue biopsy may be a bad prognostic sign in patients with MTC. This is in line with pancreatic NET (P-NETs) and GEP-NETs, where low SSTR2a tumor expression has been shown to be associated with poor outcome and more aggressive grades of tumor [28–30]. In a retrospective study in 97 patients with MTC, SSTR2a expression was significantly correlated with the presence of lymph node metastasis. However, prognosis was not investigated [8]. In MTC patients, stage IV, 10-year survival rates for SSTR2a negative patients was 43% versus 96% for SSTR2a positive patients [31].

**Limitations and future perspectives**

A limitation of the present retrospective study is the small number of patients and the heterogeneity between patients. Despite this, as very limited data of PRRT in MTC patients are currently available, the present study provides valuable insights about which patients might potentially benefit from PRRT. In addition, it clearly illustrates that this therapy may only be suitable for a highly selected group of patients.

In the present study, $^{111}$In-DTPA-octreotide scans were used to evaluate SSTR2a uptake in 35 non-treated patients, demonstrating very limited uptake compared to the liver in the majority of patients. The nowadays more commonly used $^{68}$Ga-DOTATATE PET scans have better imaging properties due to pharmacological (higher affinity to SSTR2a), technical (e.g. positron imaging, attenuation correction), as well as physical (higher gamma energies) differences and are more useful for more precise staging of the patient [32–34]. However, it is not likely that routine $^{68}$Ga-DOTATATE PET scans would have resulted in a higher percentage of patients with a more favorable uptake compared to the liver. In pulmonary and gastroenteropancreatic neuroendocrine tumours only 3 out of 78 (4%) patients were misclassified by $^{111}$In-DTPA-octreotide scans [35].

The role of other pharmaceuticals in imaging and treatment of MTC, such as metaiodobenzylguanidine (MIBG), is limited due to low sensitivity (30%) [36, 37] and the small number of patients treated with I-131-MIBG [38, 39].

**Conclusion**

PRRT using $^{177}$Lu-octreotate could be considered in MTC patients with both a high tumor uptake (≥grade 3) on $^{111}$In-DTPA-octreotide scan as well as tumor SSTR2a receptor expression by immunohistochemistry. Further research is needed to evaluate the effectiveness in these patients. Our retrospective data of 35 non-treated MTC patients, suggest that only minority of patients are eligible for $^{177}$Lu-octreotate therapy.
Abbreviations
CEA: carcinoembryonic antigen; CI: confidence interval; CT: Calcitonin; GEP-NETs: gastroenteropancreatic neuroendocrine tumors; HR: hazard ratio; MBG: metaiodobenzylguanidine; MTC: medullary thyroid carcinoma; OS: Overall Survival; PD: progressive disease; PFS: progression-free survival; P-NETs: pancreatic neuroendocrine tumors; PR: partial response; PRRT: peptide receptor radionuclide therapy; RECIST: Response Evaluation Criteria In Solid Tumors; RET: rearranged during transfection; SD: stable disease; SSTR: somatostatin receptor; TKI: Tyrosine kinase inhibitor; uptake grade 1: uptake < normal liver uptake; uptake grade 2: uptake equal to normal liver uptake; uptake grade 3: uptake > normal liver uptake; uptake grade 4: uptake > normal spleen or kidneys uptake; WHO: world health organization

Acknowledgements
Not applicable.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
CB analyzed and interpreted the patient data and was a major contributor in writing the manuscript. TB, BK and LF treated patients with PRRT, interpreted scans and contributed in writing. FN, MV and LH interpreted pathology and contributed in writing. WH, WV and YR was responsible for analyzing laboratory measurements and revised the manuscript. GF contributed as surgeon and revising the manuscript. WH, WV and CB analyzed and interpreted the patient data and was a major contributor in writing the manuscript. TB, BK and LF treated patients with PRRT, interpreted scans and contributed in writing. FN, MV and LH interpreted pathology and contributed in writing. WH, WV and YR was responsible for analyzing laboratory measurements and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of the Erasmus Medical Center (127.545/1993/84) and written informed consent was obtained from participants. Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Erasmus MC, Department of Internal Medicine, Academic Center for Thyroid Diseases, European Neuroendocrine Tumor Society center of excellence, P.O Box 2040, 3000, CA, Rotterdam, the Netherlands. 2Erasmus MC, Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, P.O Box 2040, 3000, CA, Rotterdam, the Netherlands. 3Erasmus MC, Department of Pathology, Erasmus University Medical Center, P.O Box 2040, 3000, CA, Rotterdam, the Netherlands.

Received: 22 January 2019 Accepted: 28 March 2019
Published online: 05 April 2019

References
1. Hundahl SA, Fleming ID, Frengemen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83(12):2638–48.
2. Wells SA Jr, Asa SL, Dufle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JR, Pacini F, et al. Revised American Thyroid Association-guidelines for the management of medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2015;25(6):567–610.
3. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.
4. Wells SA Jr, Robinson BG, Gagel RF, Dufle H, Fagin JA, Santoro M, Baudoin E, Elisei R, Jarzab B, Vasselli JR, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.
5. Papotti M, Croce S, Bello M, Bongiovanni M, Allia E, Schindler M, Bussolati G. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 2001;439(6):787–97.
6. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, deh Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001;86(2):361–9.
7. Reubi JC, Chaviale IA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64(5):567–73.
8. Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Kopperer O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMA. 2016;124(10):839–45.
9. Frank-Raue K, Bihl H, Dorr U, Buh H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42(1):31–7.
10. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76(6):1413–7.
11. Treglia G, Tamburrolo A, Giovannello L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16(4):362–72.
12. Strosberg J, El-Haddad G, Wolin E, Jansen C, Chason B, Mittra E, Kurz PL, Kulke MH, Jacene H, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(12):125–35.
13. Ifen T, Muller B, Schindler C, Rochlitz C, Oertl D, Macke HR, Muller-Brand J, Walter MA. Response to 90Y-DOTA-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(22 Pt 1):6966–702.
14. Vaisman F, de Castro PH, Lopes FP, Kendall PB, Pessoa CH, Balzico DA, de Carvalho Leal D, Vilhena B, Vaisman M, Carneiro M, et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med. 2015;40(2):123–7.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, D'Anzico S, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
16. Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361–8.
17. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijk CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754–62.
18. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijk CH, Fraassien GH, Krenning EP, Kwekkeboom DJ. Long-term efficacy, survival, and safety of [177Lu-DOTA(OH)2]Tyr3]octreotide in patients with Gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24.
19. Institute NC. Common terminology criteria for adverse events v4.0 in: NIH publication. Vol. In: 09–747, 2005.
20. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2012;42(2):84–91.
21. Kasajima A, Papotti M, Ito W, Brizzi ML, Salvia A, Rapa I, Tachibana T, Yazdani S, Sasano H, Volante M. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol. 2018;72:144–52.
22. de Groot JW, Kema IP, Beukelaar H, van der Veen E, Wiggers T, Plukker JT, Wolffenbuttel BH, Links TP. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2006;16(11):1163–70.
23. Kaltsas G, Androulakis IL, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010;17(3):R173–93.
24. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278–85.

25. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.

26. Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human cancers. Cancer. 1999;85(1):188–98.

27. Roman S, Hewitt J, Yakubovitz S, Anzurit A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol. 2000;278(6):H1815–22.

28. Okuwaki K, Kida M, Mikami T, Yamauchi H, Imai K, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, et al. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119(23):4094–102.

29. Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L, Feng S, Zhou Z, Shao C, Chen M, et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165–74.

30. Mehta S, de Reuver PR, Gill P, Andrici J, D’Unso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ. Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors. Medicine (Baltimore). 2015;94(40):e1281.

31. de Vries LH, Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, Schepers A, Bonenkamp HJ, van Engen-van Grunsven I, Kuijf S et al. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine. 2018.

32. Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebel IS, Goke B, Cummings P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56.

33. Ruf J, Heuck F, Schiefer J, Denecke T, Egert F, Pascher A, Pavel M, Stelter L, Klopf S, Wiedenmann B, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91(1):101–9.

34. Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872–8.

35. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of Neuroendocrine Tumors. J Nucl Med. 2016;57(3):708–14.

36. Baulieu JL, Guillouet MC, Delisle MJ, Perdriscot R, Gardet P, Delpepe N, Baulieu F, Dupont A, Talbot JN, Coutins G, et al. Radiolabeled metaiodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer. 1987;60(9):2189–94.

37. Skouroi E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4):e8156.

38. Mazza JC, Grunenwald S, Otaal P, Vezzoli D, Bennet A, Caron P. Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma. Thyroid - official journal of the American Thyroid Association. 2012;22(6):654–5.

39. Castellani MR, Seregini E, Maccarone M, Chiesa C, Aliberti G, Oruguesu E, Bombardieri E. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging. 2008;52(4):390–40.